Francisco Javier
López Jiménez
Profesor/a Asociado/a en CC. de la Salud
Carlos
Solano Vercet
Carlos Solano Vercet-rekin lankidetzan egindako argitalpenak (33)
2024
-
Omicron SARS-CoV-2 infection management and outcomes in patients with hematologic disease and recipients of cell therapy
Frontiers in Oncology, Vol. 14
-
Real-World Experience with Isavuconazole in Allogeneic Stem Cell Transplantation in Spain
Transplantation and Cellular Therapy, Vol. 30, Núm. 10, pp. 1033.e1-1033.e8
2023
-
Assessment of the potential value of plasma Torque Teno virus DNA load monitoring to predict cytomegalovirus DNAemia in patients with hematological malignancies treated with small molecule inhibitors: A proof-of-concept study
Journal of medical virology, Vol. 95, Núm. 7, pp. e28933
-
Immunobiology of cytomegalovirus infection in patients with haematological malignancies undergoing treatment with small molecule inhibitors
British Journal of Haematology, Vol. 200, Núm. 6, pp. e58-e61
-
One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients
Blood Cancer Journal, Vol. 13, Núm. 1
-
Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients
Viruses, Vol. 15, Núm. 10
2022
-
SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group
American Journal of Hematology, Vol. 97, Núm. 1, pp. 30-42
2021
-
Assessment of the association between cytomegalovirus DNAemia and subsequent acute graft-versus-host disease in allogeneic peripheral blood stem cell transplantation: A multicenter study from the Spanish hematopoietic transplantation and cell therapy group
Transplant Infectious Disease, Vol. 23, Núm. 4
-
Cytomegalovirus-specific T-cell immunity and DNAemia in patients with chronic lymphocytic leukaemia undergoing treatment with ibrutinib
British Journal of Haematology
2019
-
Frequency, characteristics, and outcome of PTLD after allo-SCT: A multicenter study from the Spanish group of blood and marrow transplantation (GETH)
European Journal of Haematology, Vol. 102, Núm. 6, pp. 465-471
-
Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant
Biology of Blood and Marrow Transplantation, Vol. 25, Núm. 9, pp. 1825-1831
2017
-
IL28B genetic variation and cytomegalovirus-specific T-cell immunity in allogeneic stem cell transplant recipients
Journal of Medical Virology, Vol. 89, Núm. 4, pp. 685-695
2016
2015
-
Cytomegalovirus infection management in allogeneic stem cell transplant recipients: A national survey in Spain
Journal of Clinical Microbiology, Vol. 53, Núm. 8, pp. 2741-2744
-
Enumeration of NKG2C+ natural killer cells early following allogeneic stem cell transplant recipients does not allow prediction of the occurrence of cytomegalovirus DNAemia
Journal of Medical Virology, Vol. 87, Núm. 9, pp. 1601-1607
-
Functional patterns of cytomegalovirus (CMV) pp65 and immediate early-1-specific CD8+ T cells that are associated with protection from and control of CMV DNAemia after allogeneic stem cell transplantation
Transplant Infectious Disease, Vol. 17, Núm. 3, pp. 361-370
2014
-
An evaluation of the role of NKG2C+ natural killer cells in protection from cytomegalovirus DNAemia early following allogeneic stem cell transplantation
Journal of Medical Virology, Vol. 86, Núm. 5, pp. 806-811
-
Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation
Haematologica, Vol. 99, Núm. 10, pp. 1632-1637
2012
-
Functional profile of cytomegalovirus (CMV)-specific CD8 + T cells and kinetics of NKG2C + NK Cells associated with the resolution of CMV DNAemia in allogeneic stem cell transplant recipients
Journal of Medical Virology, Vol. 84, Núm. 2, pp. 259-267